getimage-48-768x274.png
Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on March 10
March 03, 2022 09:15 ET | Capricor Therapeutics
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development
March 02, 2022 09:00 ET | Capricor Therapeutics
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in the U.S.
January 25, 2022 05:00 ET | Capricor Therapeutics
-Partnership Leverages Nippon Shinyaku’s Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.- -Capricor to Receive an Upfront Payment of $30 Million,...
getimage-48-768x274.png
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
December 13, 2021 09:15 ET | Capricor Therapeutics
Capricor’s Exosome-based mRNA Vaccine for SARS-CoV-2-In-Vivo Preclinical Data Published in the Journal of Biological Chemistry--Preclinical Data Demonstrates Strong T-Cell Response for High Conserved...
getimage-48-768x274.png
Capricor’s CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day
November 12, 2021 09:15 ET | Capricor Therapeutics
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and...
getimage-48-768x274.png
Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 09, 2021 16:05 ET | Capricor Therapeutics
CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy-Phase 3 Pivotal Study Cleared to Proceed--Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at...
getimage-48-768x274.png
Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9
November 02, 2021 16:05 ET | Capricor Therapeutics
LOS ANGELES, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
September 24, 2021 07:00 ET | Capricor Therapeutics
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)– –Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction...
getimage-48-768x274.png
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
September 22, 2021 16:05 ET | Capricor Therapeutics
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 - - The Cell & Gene Meeting on the Mesa Annual Conference: October 13 - LOS ANGELES, Sept. 22, 2021 (GLOBE NEWSWIRE) --...
getimage-48-768x274.png
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 09:00 ET | Capricor Therapeutics
LOS ANGELES, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...